KM Biologics announces promising results of Phase I clinical study of dengue vaccine KD-382

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    Global Banking News (GBN). 03/25/2021.
  • Additional Information
    • Abstract:
      Japanese biologics company KM Biologics Co Ltd on Thursday updated the results of its Phase I clinical study of the vaccine KD-3821 for the prevention of dengue, a mosquito-borne virus belonging to the Flaviviridae family.